ABVC BIOPHARMA, INC.
ABVC evidence brief
What we can confirm
- Market Cap:
- $28.0M
What it means
What to watch
Prepared research question
What matters most for ABVC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABVC
ABVC BIOPHARMA, INC. is a clinical-stage biopharmaceutical company focused on advancing Phase I and II drug and medical device candidates in oncology, CNS, and ophthalmology through in-licensing from Asia-Pacific research institutions and out-licensing to larger pharmaceutical partners.
Key risk: Zero cash reserves
Market Cap
$28.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
ABVC BIOPHARMA, INC. is a clinical-stage biopharmaceutical company focused on advancing Phase I and II drug and medical device candidates in oncology, CNS, and ophthalmology through in-licensing from Asia-Pacific research institutions and out-licensing to larger pharmaceutical partners.
- Cash & equivalents were $0.0M as of 2026-06-30 [sec].
- Net income was -$0.7M as of 2026-06-30 [sec].
- Shareholders' equity was $10.3M as of 2026-06-30 [sec].
- Phase II trials for ABV-1519 (non-small cell lung cancer) and ABV-1703 (pancreatic cancer) are expected to begin in Q4 2026 [sec_mda · as of 2026-08-12].
- The company's strategy includes advancing ABV-1701 Vitargus® for retinal detachment/vitreous hemorrhage to pivotal trials and out-licensing post-Phase II products [sec_mda · as of 2026-05-18].
What works
- ABVC has a diversified pipeline across oncology, CNS, and ophthalmology, with multiple candidates in Phase II, including ABV-1505 (ADHD) and ABV-1703 (pancreatic cancer) [sec_mda · as of 2026-08-12].
- The company employs an asset-light model by in-licensing from Asia-Pacific research institutions and out-licensing post-Phase II products to larger pharmaceutical companies, reducing late-stage development costs [sec_mda · as of 2026-08-12].
- ABVC has established clinical trial collaborations with reputable institutions such as UCSF, Taipei Veterans General Hospital, and Cedars Sinai Medical Center [sec_mda · as of 2026-08-12].
What to weigh
- Cash & equivalents were $0.0M as of 2026-06-30, indicating potential funding constraints for ongoing operations and clinical trials [sec].
- The company reported a net loss of -$0.7M as of 2026-06-30, reflecting ongoing negative cash flow [sec].
- Clinical development of ABV-2002 (corneal storage solution) has been temporarily suspended due to funding constraints [sec_mda · as of 2026-08-12].
- ABVC's pipeline faces intense competition; for example, ABV-1501 (triple-negative breast cancer) has 17 competitors including AstraZeneca and Merck [pipeline].
From the filings
Quoted directly from source documents.
ABV-2002 development suspended due to funding
“Further clinical development has been temporarily suspended due to funding constraints.”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Zero cash reserves — Cash & equivalents were $0.0M as of 2026-06-30, severely limiting operational flexibility [sec].
- Ongoing net losses — Net income of -$0.7M as of 2026-06-30 indicates continued cash burn without near-term revenue [sec].
- Clinical trial suspension — ABV-2002 development suspended due to funding constraints, highlighting financial fragility [sec_mda · as of 2026-08-12].
- Intense pipeline competition — ABV-1501 faces 17 competitors including major pharma, increasing risk of market failure [pipeline].
What to watch
- Initiation of Phase I/II trial for ABV-1519 (non-small cell lung cancer) expected in Q4 2026 [sec_mda · as of 2026-08-12].
- Initiation of Phase II trial for ABV-1703 (pancreatic cancer) expected in Q4 2026 [sec_mda · as of 2026-08-12].
- Progress of ABV-1701 Vitargus® toward pivotal trials for retinal detachment/vitreous hemorrhage [sec_mda · as of 2026-05-18].
- Ability to secure additional funding given zero cash position and ongoing net losses [sec].
Sources: Pipeline · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run ABVC BIOPHARMA, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ABVC BIOPHARMA, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$792K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 221,169 | $215K |
| vanguard capital management llc | 190,574 | $185K |
| vanguard fiduciary trust co | 97,363 | $94K |
| renaissance technologies llc | 95,100 | $92K |
| state street corp | 72,800 | $71K |
| blackrock, inc. | 56,442 | $55K |
| northern trust corp | 32,087 | $31K |
| two sigma securities, llc | 21,023 | $20K |
| dimensional fund advisors lp | 12,227 | $12K |
| squarepoint ops llc | 10,547 | $10K |
Showing top 10 of 13 institutional holders of ABVC BIOPHARMA, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 29, 2026- % of float
- 1.4%
- Days to cover
- 2.4
- Shares short
- 295,274
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABVC short interestGovernance
Frequently asked questions
What is the AI investment thesis for ABVC BIOPHARMA, INC.?
ABVC BIOPHARMA, INC. is a clinical-stage biopharmaceutical company focused on advancing Phase I and II drug and medical device candidates in oncology, CNS, and ophthalmology through in-licensing from Asia-Pacific research institutions and out-licensing to larger pharmaceutical partners.
Who is the CEO of ABVC BIOPHARMA, INC.?
Dr. Uttam Yashwant Patil Ph.D. is the chief executive officer of ABVC BIOPHARMA, INC. (ABVC).
Where is ABVC BIOPHARMA, INC. headquartered?
ABVC BIOPHARMA, INC. (ABVC) is headquartered in Fremont, CA, United States.
What therapeutic areas does ABVC BIOPHARMA, INC. focus on?
ABVC BIOPHARMA, INC. develops therapies across Oncology, Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.